Anavo Therapeutics BV
Hsu-Min Sung has held several research positions in the field of cancer cell biology. They began their career as a Graduate Research Fellow at the University of Heidelberg in 2013 and remained in this role until 2018. Following this, they joined the Vrije Universiteit Brussel as a Postdoctoral Research Fellow in 2019, where they worked until 2020. In 2020, Sung became a Postdoctoral Researcher at Universitätsmedizin Göttingen, leaving this position in 2022. Currently, they hold the position of Senior Cancer Cell Biologist at Anavo Therapeutics BV, starting in April 2022.
Hsu-Min Sung completed a Doctor of Philosophy (PhD) degree in Molecular Biology and Cancer Biology at Heidelberg University from 2013 to 2018. Prior to that, from 2010 to 2012, they obtained a Master's degree in Virology and RNA Biology from National Yang Ming University. Hsu-Min Sung began their academic journey with a Bachelor's degree in Biology, General at National Central University, which they completed from 2006 to 2010.
This person is not in any offices
Anavo Therapeutics BV
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications